BTK
Bruton’s tyrosine kinase (BTK; EC 2.7.10.2) is a non-receptor tyrosine kinase belonging to the Tec family of kinases (TFKs), which form the second largest family of cytoplasmic tyrosine kinases in mammalian cells and include, in addition to BTK, Tec, Itk, Txk (also known as Rlk), and bone marrow tyrosine kinase gene on chromosome X (Bmx). Btk is critical for B-cell development, differentiation, and signaling. Moreover, BTK expression is assumed to be a prerequisite for B-cell proliferation and survival. Btk is the only member of the TFKs reported to be associated with human disease (primary immunodeficiency, named X-linked agammaglobulinemia (XLA) and a milder form: X-linked immunodeficiency (Xid))[1].
[1] A.J. Mohamed. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immun. Reviews. 2009, 228, 58-73.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 4141 | Acalabrutinib | Orally active, irreversible, and highly selective second-generation BTK inhibitor | Inquire | |
| 2226 | AVL 292 | Potent, selective, covalent BTK inhibitor | €110.00 | |
| 2018 | CGI 1746 | Inhibitor of Bruton's tyrosine kinase (BTK) | €50.00 | |
| 2862 | LFM-A13 | Inhibitor of Bruton's tyrosine kinase (BTK) | €90.00 | |
| 3466 | MT-802 | Potent and rapid degrader of BTK; PROTAC | €280.00 | |
| 1858 | PCI 32765 | Inhibitor of Bruton's tyrosine kinase (BTK) | €60.00 | |
| 3869 | RN486 | Selective and reversible inhibitor of Bruton's tyrosine kinase (BTK) | Inquire | |